Completed PHASE2 INTERVENTIONAL 10-arm NCT01399853

A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants

Sponsor: Bejing Vigoo Biological Co., LTD

Interventions (without adjuvant) 640U /0.5ml 0/0.5ml placebo 160U /0.5ml EV71 Vaccine 320U /0.5ml EV71 vaccine 640U /0.5ml EV71 vaccine

Updated 5 times since 2017 Last updated: May 29, 2012 Started: Jul 31, 2011 Primary completion: Nov 30, 2011 Completion: May 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01399853, this PHASE2 trial focuses on Immunogenicity and Safety and remains completed. Sponsored by Bejing Vigoo Biological Co., LTD, it has been updated 5 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bejing Vigoo Biological Co., LTD
Jiangsu Province Centers for Disease Control and Prevention

Data source: Jiangsu Province Centers for Disease Control and Prevention

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nanjing, China